招生導(dǎo)師簡介

1、招生導(dǎo)師簡介一、個人簡介198奔畢業(yè)于中國預(yù)防醫(yī)科院病毒學(xué)研究所獲碩士學(xué)位.研究員,博士生導(dǎo)師,現(xiàn)任病毒肝炎室主任.屢次承當(dāng)國家“九五、“十五、“十一五、“十二五攻關(guān)和973、863重大專項等課題研究.擔(dān)任過中華人民共和國藥典委員會委員、中華醫(yī)學(xué)會免疫診斷專家委員會委員、國家科技部創(chuàng)新基金評審委員會委員、中國肝炎基金會理事、中國遺傳學(xué)會青年委員會委員、中華實驗和臨床病毒學(xué)雜志副主編編委、中國醫(yī)療事故鑒定委員會委員、北京市自然基金委員會評委、病毒學(xué)報編委等社會兼職.曾榮獲戊型肝炎病原學(xué)及流行病學(xué)研究的衛(wèi)生部一等獎；戊型肝炎病毒學(xué)及流行病學(xué)研究的國家級科技進步二等獎；丙型肝炎分子生物學(xué)、血清學(xué)診斷

2、方法的研究和臨床應(yīng)用的衛(wèi)生部科技進步一等獎；丙型肝炎分子生物學(xué)、血清學(xué)診斷方法的研究和臨床應(yīng)用的國家級科技進步二等獎；戊型肝炎病毒分子生物學(xué)、血清學(xué)及散發(fā)性戊型肝炎研究的衛(wèi)生部科技進步二等獎；丙型肝炎分子生物學(xué)、血清學(xué)診斷方法的研究和臨床應(yīng)用的北京市科技進步一等獎；中華預(yù)防醫(yī)學(xué)會科學(xué)技術(shù)一等獎.先后獲得中國青年科學(xué)家獎、中央國家機關(guān)十大杰出青年稱號以及衛(wèi)生部突出奉獻中青年專家獎等.在國內(nèi)外發(fā)表科學(xué)論文百余篇,對我國病毒性疾病的研究和防控工作做出了突出奉獻.在國內(nèi)外本專業(yè)領(lǐng)域有較高的學(xué)術(shù)地位.二、主要研究方向肝炎病毒免疫及其在預(yù)防限制中的應(yīng)用肝炎基因工程疫苗的實驗室研究和臨床考核評價生物工程上游

3、技術(shù)與下游技術(shù)的連接途徑新型病原實驗室應(yīng)對方法和快速反響技術(shù)三、代表性科研工程國家科技支撐方案：手足口病(EV71型)疫苗的研制國家十一五重大專項：我國乙型病毒性肝炎疫苗保護效果及免疫持久性的系統(tǒng)評價北京市科委：乙肝疫苗免疫評價與新型疫苗的研發(fā)四、代表性論文、成果(2021年以來)1. GenotypingofacutehepatitisAvirusisolatesfromChina,2003-2021.2021Jul;83(7):1134-41.2. HepatitisCvirus-specificcellularandhumoralimmuneresponsesfollowingimmun

4、izationwithamulti-epitopefusionprotein.IntJMolMed,2021,29(1):12-17.Epub2021Sep283. EpidemiologicalchangesinhepatitisBprevalenceinanentirepopulationafter20yearsoftheuniversalHBVvaccinationprogramme.2021,139:1159-11654. EffectivenessofaChinesehamsterovarycellderivedhepatitisBvaccineinChineseRuralCommu

5、nities.Vaccine,2021,29:3905-39085. Long-termefficacyof10T2yearsafterbeingimmunizedwithChinesehamsterovarycellderivedhepatitisBvaccineinChineseRuralCommunities_Vaccine30(2021)205120536. Ef?cacyofyeast-derivedrecombinanthepatitisBvaccineafterbeingusedfor12yearsinhighlyendemicareasinChina.Vaccine.2021,

6、30:6623-6627.7. DevelopmentofaHepatitisDeltaVirusAntibodyAssayforStudyofthePrevalenceofHDVAmongIndividualsInfectedwithHepatitisBVirusinChina.JMedViro.2021,84:445-449.8. GeneticDiversityofHepatitisAVirusinChina:VP3-VP1-2AGenesandEvidenceofQuasispeciesDistributionintheIsolates.PlosOne,2021;8(9):e74752

7、.9. EpidemiologyofHepatitisCVirusInfectionandRiskFactorAnalysisintheHebeiProvince,China.PlosOne,2021;8(9):e75586.10. ComparativeevaluationofanovelTaqManreal-timereversetranscription-polymerasechainreactionassayforhepatitisAvirusdetection.JIntMedRes,2021;42(2):427-434.11. Constructionandimmunological

8、evaluationoftruncated119152inthemajorimmunodominantregion(MIR).BBRC,2021;439:84-89.12. EpidemiologyofHepatitisEVirusinChina:ResultsfromtheThirdNationalViralHepatitisPrevalenceSurvey,2005-2006PLOSONE2021;9(10)://10.1371/journal.pone.011083713. Multiplexhydrolysisprobereal-timePCRforsimulta

9、neousdetectionofhepatitisAvirusandhepatitisEvirus.IntJMolSci,2021,15(6):9780-9788.14. MigrationPatternsofHepatitisCVirusinChinaCharacterizedforFiveMajorSubtypesBasedonSamplesfrom411VolunteerBloodDonorsfrom17ProvincesandMunicipalities.jvi.July2021Volume88Number13p.7120-712915. Riskfactorsassociatedwi

10、thimmuneprophylaxisfailureagainstmothertochildtransmissionofhepatitisBvirusandhepatitisBvaccinationstatusinYunnanprovince,China.Vaccine.2021Jun5;32(27):3362-6.16. MolecularepidemiologicalstudyofhepatitisBvirusgenotypesinSouthwest,China.JMedVirol.2021Aug;86(8):1307-1313.17. Thelong-termefficacyofChin

11、esehamsterovarycellderivedhepatitisBvaccineafterbeingusedfor14T6yearsinChineseruralcommunities.Vaccine,2021,33:294-297.18. Thelong-termefficacy,13-23years,ofaplasma-derivedhepatitisBvaccineinhighlyendemicareasinChina.Vaccine,2021,33:2704N70919. EvolutionandgeneticcharacterizationofhepatitisAvirusiso

12、latesinChina.InternationalJournalofInfectiousDiseases.2021.33,e156七158.20. Full-lengthgenomecharacterizationandquasispeciesdistributionofhepatitisAvirusisolatesinChina.VirolRep.2021.21. ImmuneresponsestoHBsAgconjugatedtoproteinDofnon-typeablehaemophilusinfluenzainmice.Plosone202110(2):e0117736.22. JikunZhou,YongZhangandShengliBi.RiskfactorsofhepatitisCvirustransmissionandgenotypedistributioninformerblooddonorsfromChineseruralarea.BMCPublicHealth(2021)15:184.DOI10.1186/s12889-015-1535-6.23. Enh